Jennifer Havens

Dr. Jennifer Havens is a naturopathic physician and clinical researcher specializing in integrative cancer care. She obtained her medical degree from Southwest College of Naturopathic Medicine (SCNM) and Health Sciences. She was awarded an NIH Ruth L. Kirschstein NRSA Fellowship at the University of Washington in Seattle, after which, she continued her clinical training as a Resident in Naturopathic Oncology at the Cancer Treatment Centers of America in Philadelphia. She completed internships in Integrative Medicine at Yale University in the Department of Pediatrics and at George Washington University in the Center for Integrative Medicine.

Prior to becoming a naturopathic physician, Dr. Havens received her doctoral training at the University of Virginia in the Department of Molecular and Cancer Biology after which she continued as a researcher working for the Department of Defense and Veterans Affairs Administration developing DNA-based molecular diagnostics for infectious disease.

Currently, Dr. Havens is the Program Director for Integrative Medicine at Children’s Wisconsin in the MACC Fund Center for Cancer and Blood Disorders. In addition to supporting the Integrative Medicine program at Children’s, she is an attending physician and faculty member at the SCNM Medical Center in Tempe, AZ. Her practice focuses on precision integrative medicine using Whole Genome Sequencing (WGS) and solid tumor biomarker analysis to inform individualized, tumor-specific treatments for adult and pediatric cancers.

She is an active member of multiple professional organizations including the Society for Integrative Oncology, the International Congress on Integrative Medicine and Health, as well as the American Society for Clinical Oncology.

Dr. Havens actively participates in clinical research and is investigating the role of Viscum album extract therapy, and modulation of disease progression in patients using conventional chemotherapeutics and targeted therapies. Additionally, she is researching the effect of Alpha-lipoic-acid and low-dose Naltrexone (LDN) on late-stage, locoregional pancreatic and hepatopancreatic cancers. She is also actively involved with a phase II clinical trial at Yale investigating the role of a small molecule natural product and the effect on the progression of disease in late-stage prostate cancer.